EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma

Georges Azzi, Mehrad Tavallai, Vasily N Aushev, Allyson Koyen Malashevich, Gregory P Botta, Mohamedtaki A Tejani, Diana Hanna, Shifra Krinshpun, Meenakshi Malhotra, Adham Jurdi, Alexey Aleshin, Pashtoon M Kasi iD

The Oncologist · 2023

DOI: 10.1093/oncolo/oyac249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Georges Azzi und 11 weiteren Autor:innen. Beteiligte Einrichtung: HolyCross Medical Group, Ft. Lauderdale, FL, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Cell-Free Nucleic Acids, Carcinoma, Squamous Cell, Anus Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anal squamous cell carcinoma (SCCA) is an uncommon malignancy with a rising incidence that has a high cure rate in its early stages. There is an unmet need for a reliable method to monitor response to treatment and assist in surveillance. Circulating tumor DNA (ctDNA) testing has shown great promise in other solid tumors for monitoring disease progression and detecting relapse in real time. This study aimed to determine the feasibility and use of personalized and tumor-informed ctDNA testing in SCCA. Patients and Methods We analyzed real-world data from 251 patients (817 plasma samples) with stages I-IV SCCA, collected between 11/5/19 and 5/31/22. The tumor genomic landscape and feasibility of ctDNA testing was examined for all patients. The prognostic value of longitudinal ctDNA testing was assessed in patients with clinical follow-up (N = 37).

Results

Whole-exome sequencing analysis revealed PIK3CA as the most commonly mutated gene, and no associations between mutations and stage. Anytime ctDNA positivity and higher ctDNA levels (MTM/mL) were associated with metastatic disease (P = .004). For 37 patients with clinical follow-up, median follow-up time was 21.0 months (range: 4.1-67.3) post-diagnosis. For patients with stages I-III disease, anytime ctDNA-positivity after definitive treatment was associated with reduced DFS (HR: 28.0; P = .005).

Conclusions

Our study demonstrates the feasibility of personalized and tumor-informed ctDNA testing as an adjunctive tool in patients with SCCA as well as potential use for detection of molecular/minuteimal residual disease, and relapse during surveillance. Prospective studies are needed to better evaluate the use of ctDNA testing in this indication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNACell-Free Nucleic AcidsCarcinoma, Squamous CellAnus NeoplasmsHumansBiomarkers, TumorNeoplasm Recurrence, LocalDNA, NeoplasmMutation

Stichwörter der Autor:innen

anal squamous cell carcinomacirculating tumor DNAminimal/molecular residual diseaseprognostic biomarker

Substanzen

Circulating Tumor DNACell-Free Nucleic AcidsBiomarkers, TumorDNA, Neoplasm

Autor:innen und Institutionen

  • HolyCross Medical Group, Ft. Lauderdale, FL, USA.
  • Natera, Inc., Austin, TX, USA.
  • UC San Diego Health, San Diego, CA, USA.
  • AdventHealth Cancer Institute, Orlando, FL, USA.
  • USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Weill Cornell Medicine, New York, NY, USA.

ORCID-Profile: Pashtoon M Kasi

Zitieren

APA

Azzi, G., Tavallai, M., Aushev, V. N., Koyen Malashevich, A., Botta, G. P., Tejani, M. A., Hanna, D., Krinshpun, S., Malhotra, M., Jurdi, A., Aleshin, A., & Kasi, P. M. (2023). Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyac249

Vancouver

Azzi G, Tavallai M, Aushev VN, Koyen Malashevich A, Botta GP, Tejani MA, et al. Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma. The Oncologist. 2023. doi:10.1093/oncolo/oyac249

BibTeX
@article{Azzi2023,
  author = {Azzi, Georges and Tavallai, Mehrad and Aushev, Vasily N and Koyen Malashevich, Allyson and Botta, Gregory P and Tejani, Mohamedtaki A and Hanna, Diana and Krinshpun, Shifra and Malhotra, Meenakshi and Jurdi, Adham and Aleshin, Alexey and Kasi, Pashtoon M},
  title = {Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyac249}
}
Kostenlos starten →